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Abstract
With the growing concerns in the scientific and health communities over increasing
levels of antibiotic resistance, antimicrobial peptide bacteriocins have emerged as
promising alternative to conventional small molecule antibiotics. A substantial attention
has recently focused on the utilization of bacteriocins in food preservation and health
safety. Despite the fact that a large number of bacteriocins have been reported, only a
few have been fully characterized and structurally elucidated. Since knowledge of the
molecular structure is a key for understanding the mechanism of action and therapeutic
effects of peptide, we centered our focus in this review on the structure-activity
relationships of bacteriocins with a particular focus in seven bacteriocins, namely, nisin,
microcin J25, microcin B17, microcin C, leucocin A, sakacin P, and pediocin PA-1.
Significant structural changes responsible for the altered activity of the recent bacteriocin
analogues are discussed here.

KEYWORDS: Bacteriocins, Structure-Activity Relationship, Bacteriocin Analogues
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1. INTRODUCTION
Eukaryotic and prokaryotic cells produce ribosomally synthesized antimicrobial peptides
that have significant effect against several harmful microorganisms [1]. When produced
by bacteria, these antimicrobial peptides are referred to as bacteriocins [2]. Bacteriocins
were first discovered by A. Gratia in 1925 when he was involved in the process of
searching for approaches to kill bacteria. He called his first bacteriocin that killed E. coli
a colicin [3].

Generally bacteriocins are small, very potent antimicrobial peptides

(proteinaceous toxins), made by bacteria to inhibit the growth of alike or closely related
bacterial strains. Typically bacteriocins have narrow spectrum of activity; however, few
of them are shown with broad spectrum and wide range of activities. Bacteriocins have
also been considered as analogous to yeast and paramecium killing agents, which are
structurally and functionally different [4-7].

Throughout the years of discovery, several approaches have been taken to classify
bacteriocins into a number of categories that include nature of the producing strains, the
methods by which these molecules are produced, common resistance mechanisms and the
peptides mechanism of actions [1]. The most widely studied bacteriocins are classified
into class I and class II bacteriocins. Class I consists of small, heat stable (<10 kDa)
post-translationally modified peptides, while class II are small, heat stable (<10 kDa) less
extensive post-translationally modified peptides, and each class is further divided into
subclasses based on structure and modifications (Table 1). Bacteriocins are very potent
antimicrobial peptides typically active in the nanomolar range, and some of them are
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produced by food grade microorganisms rendering them extremely safe and potential
candidates for applications in food safety and clinical settings [2, 8].
Table 1. Classification of bacteriocins
Bacteriocins

Features

Example*

Class I
 Class Ia (Lantibiotic)
- Type A
- Type B
- Type C

Post-transtionaly modified
Elongated (< 4KDa)
Globular (1.8 to 2.4 KDa)
Two-peptide lantibiotics

Nisin, Pep5, Epidermin
Lacticin 481, Cinnamycin
Haloduracin




Class Ib (Sactibiotics) Hold sulphur–α-carbon linkages
Class Ic
Carbacyclic lantibiotics
(Labyrinthopeptins)

Subtilosin A, Thuricin CD
Labyrinthopeptin A2



Microcins

MccJ25, MccB17, MccC

Class II


Class IIa



Class IIb



Class IIc (circular)



Class IId



Class IIe

Class III

Lasso structure, heterocycle
containing or others
Less modified or circular

Pediocin PA1 like bacteriocins Pediocin PA1, Leucocin A,
(conserved N-terminal domain Sakacin P, Curvacin A
with a YGNGV sequence)
Two-peptide bacteriocin
Lactoccocin G, Plantaricin
EF, Plantaricin JK
N- and C- termini are covalently Enterocin AS48, Circularin
linked together
A, Gassericin A
Unmodified bacteriocin, linear,
MccV, MccL, Mcc24
non-pediocin-like
Colicin V-like bacteriocin, and
MccE492, MccH47
Siderophore-microcin family
Large peptides (>10 kDa)

 Class IIIa
Bacteriolysins (lytic action)
Lysostaphin
 Class IIIb
Non-lytic bacteriocins
Helveticin J
*The names of peptides discussed in detail in this review are highlighted in bold.
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Bacteriocins are quite unique with respect to their mechanism of action [9, 10]. In
general, bacteriocins act via interactions with a specific receptor on the target cell. This
interaction leads to permeabilization of the cell membrane of the target cell, triggering
outflow of intracellular components and disintegration of the proton-motive force. For
instance, Nisin and other lantibiotics bind to lipid II as a target molecule to kill the
bacteria [10, 11]. Recently it has been revealed that lipid II is the target of several
antibiotics and antifungal agents.

Certain peptides of class II bacteriocins such as

pediocin-like bacteriocins and lactococcins bind to specific membrane active receptors in
order to express their activity.

A membrane protein component of the mannose

phosphotransferase (man-PTS) system has been revealed to be the actual target site of
these bacteriocins [12-14]. Not only bacteriocins from Gram-positive bacteria are using
the man-PTS as the target for killing cells, it has been shown that certain microcins from
Gram-negative bacteria required this membrane receptor to show activity [15, 16].

Despite the long-history of bacteriocins, only nisin and few other bacteriocins have
reached market and have been used in industry as food preservatives with very little
resistance development [8, 17]. There are clear limitations in the industrial and clinical
applications of bacteriocins, which is a result of a number of drawbacks and challenges
that have yet to be resolved. Many of these AMPs are prone to degradation by digestive
enzymes and metabolic proteins present in the food products, GI tract and blood
circulation [18-22]. Stability at harsh environments is also an issue for bacteriocins; as
an example, lantibiotics undergo oxidation in basic pH, resulting in loss of its main
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bacteriocidal activity [20, 23]. Existence of such disadvantages and the scientists desire to
exploit the prospects of bacteriocins as safe and potent antibacterial agents have driven
much effort towards exploring the structural-activity relationships (SARs) of
bacteriocins. The better understanding of the SARs can render more stable highly active
analogues with higher possibility of developing novel antibiotics from bacteriocins.

In this review we center our focus on the structural-activity relationships of bacteriocins,
reviewing the recent novel analogues of the most-well characterized bacteriocins,
discussing the challenges that hinder bacteriocins from being on the marketplace and
finally stressing on the future potential of the analogues.

2. CLASS I BACTERIOCINS
Class I bacteriocins are ribosomally synthesized, small membrane-active antimicrobial
peptides with molecular sizes of <5 kDa. Generally, they contain unusual amino acids
such as lanthionine or b-methyl lanthionine in their sequences and are therefore called
post-translationally modified bacteriocins [24].

Nisin is the most well studied and

characterized AMP of class I bacteriocins. The class has been subdivided into three
categories including, class Ia (the lantibiotics), class Ib (the sactibiotics) and class Ic (the
labyrinthopeptins) [1].

In general, lantibiotics or class Ia peptides contain more than one post-translationally
modified amino acid residue. These could be lanthionine (Lan), methyl lanthionine
(MeLan),

dehydroalanine

(Dha),

dehydrobutyrine
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(Dhb),

2-oxobutyryl,

aminovinylmethyl-D-cysteine, labionin (Lab), or other similar modified amino acid
residues. Due to structural complexity class Ia bacteriocins are further subdivided into
three classes, namely, type A (linear), type B (globular), and type C (two-peptide) [25].
The linear or the type A lantibiotics includes nisin, pep5, epidermin and subtilin, which
were assembled on the basis of sequence length (~34 amino acid residues) and
amphiphilic structure. On the other hand, globular lantibiotics or type B that include
lacticin 481, mercsacidin, cinnamycin, and mutacin II, were assembled together
according to their compact structures and length of amino acid residues (~19 residues)
[25]. Type C are two-peptide bacteriocins where two separate sequences together display
synergistic activity.

Lantibiotics are typically produced by Gram-positive bacteria,

mainly lactic acid bacteria (LAB), to target other bacterial species such as Listeria
monocytogenes, Clostridium botulinum, Enterococcus and the resistant strains of
Staphylococcus aureus.

Another type of class I bacteriocins are microcins that are produced ribosomally by
Gram-negative Enterobacteria as host defence molecules, to strive and thrive in the midst
of bacterial community [26-29]. Microcins are classified into class I and class II on the
basis of molecular masses, disulfide bridges, and the extent of posttranslational
modification. Class I microcins are small sized (< 5 kDa) and highly post-translationally
modified peptides, like Microcin J25 (MccJ25), MccB17, and MccC (C7-C51). Class II
are comparatively higher molecular mass antimicrobial peptides (>5 to <10 kDa) with
subtle or no post-translational modifications. As compared to other bacterial origin
antimicrobial peptides, like colicins (high molecular size derived from Gram-negative
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bacteria) [30, 31] and bacteriocins derived from Gram-positive bacteria [1, 32], microcins
have been studied to a lesser extent. Till date, fourteen microcins have been discovered
and out of this, eight have been characterized structurally and to some extent functionally
[1]. Most of the well-characterized microcins belong to class I and have been studied
using SARs dealing with substitutions, deletion, truncation or other modifications of the
original sequence. As we see in literature, most of the works have taken place on some of
the microcins like MccJ25, MccB17, Mcc C7/C51, MccE492 and Mcc M, V and L;
therefore in this section of review our discussion will revolve around these peptides.

Extensive reviews have been reported for lantibiotics [9, 33-39], therefore here we will
limit our discussion to four class I bacteriocins, namely, nisin, microcins MccJ25,
MccB17, and MccC.

2.1

Nisin

Nisin, the most popular class I bacteriocin first marketed in England in 1953, is now
approved for use as a food preservative in 48 countries.[24] The full structure of nisin,
however, was elucidated in early 1970s [40]. It has several natural variants, including
nisin A (res 27-His) and nisin Z (res 27-Asn) as most common forms (Table 2). Nisin
typically contains one lanthionine (ring A) and four methyl lanthionine rings (rings B-E),
along with three dehydrated amino acid residues as shown in Fig (1). This highly potent
peptide is not only active against the important food-spoilage bacteria such as Listeria
monocytogenes and Clostridium botulinum, but also has a potential for use as a human
therapeutic, especially for treatments of drug-resistant bacterial infections [41-44].
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Table 2. Amino acid sequences of common variants of Nisin in nature.

Abu: aminobutyric acid; Dha: Dehydroalanine; Dhb: Dehydrobutyrine; ring S is only shown for
the Nisin A here, however, it is similarly present in all the variants.
In order to explore the SARs of nisin, several analogues have been made since its
discovery using either site directed mutagenesis or chemical synthesis. A number of
mutations at rings A and B have been implemented (Fig 1a) [45]. The findings showed
that a large number of nisin mutants indeed retained the biological activity of the peptide.
In fact, some double and triple mutants presented higher potency than the wild type nisin
against the indicator microorganisms. The study also suggested that introduction of a
positive charge to the ring A has a positive impact on nisin’s biological activity. Among
the mutations on ring A, only three mutants were matching the native peptide, as they do
not possess aromatic residues in the ring A. This is an indication of flexibility of the ring
A with regard to the amino acid substitutions [45]. In contrast to ring A, ring B was found
to be very sensitive to amino acid exchanges. Size of amino acids is a dispute as bulky
residues give poor or no activity. The loss of ability to cyclize the ring B between
positions 8 and 11 diminished peptide activity. Further explorations were performed by
making truncated analogues of the peptide where residues 23–34 were alternated.
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Fig. (1). Analogues of nisin A with mutations at positions 4/5/6 or 9/10 or the hinge
region (positions 20/21/22). The five rings are labeled as A, B, C, D, and E. (A) Nisin A
analogues with high activity are shown in black, weakly-active in green and inactive
mutants are presented in red. (B) Coded circles (gray color) show the activity enhancing
amino acid substituents. AAA derivative of Nisin A displayed higher activity than the
native nisin.
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Substantial reduction in activity was observed in most cases; however, when the triple
mutant KFI and the native nisin were truncated, there were only 10-fold loss of activity
compared to the wild type nisin. Additional studies of their mechanism of actions
indicated that these peptides act solely by interference with lipid II and cell-wall
biosynthesis.

In recent years, the hinge region of nisin has also received considerable attention, where
several mutations have been tried [46]. Interestingly, three mutants, N20P, M21V and
K22T, showed activity greater than the native type nisin A. While the mutants N20P and
K22T displayed activity against S. aureus and Streptococcus agalactiae, respectively, the
M21V mutant displayed activity against Listeria monocytogenes, suggesting a potential
use as a food preservative.

Nisin recently went through several bioengineering processes in order to improve its
function and physico-chemical properties. A notable example in a report by Des Field et
al [47] showed novel nisin variants with enhanced activity against clinical and foodborne
pathogens. In their study, they screened a randomized bank of nisin A producers and
identified a variant with a serine to glycine change at position 29 (S29G), with enhanced
efficacy against S. aureus SA113 Fig (1a). Furthermore, using the site-directed
mutagenesis, they generated three more derivatives of nisin A (S29A, S29D and S29E)
with enhanced activity against a range of Gram-positive drug resistant bacteria. In
addition, a number of the nisin S29 derivatives exhibited superior antimicrobial activity
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to nisin A when evaluated against a range of Gram-negative food-borne pathogens,
including E. coli, Salmonella enterica and Cronobacter sakazakii [47].

Further exploration by Cotter and co-workers showed that altering the three amino acids
at the hinge region ((N20, M21 and K22), which separates the two domains of nisin and
allows for conformational flexibility with other amino acid residues (AAK, NAI or SLS),
display enhanced bioactivity against a variety of target strains [48] (Fig 1b).
Furthermore, the structure of the mature nisin A peptide derivative AAA has been
revealed to exhibit a higher inhibition to bacterial growth than the native nisin A. The
study suggested that addition of small chiral amino acids such as alanine or serine to the
hinge region resulted in an increase in bioactivity of the peptide and it can most likely be
attributed to an increase in the ‘hinge’ flexibility. In contrast, the assembly of the achiral
glycine in the ‘hinge’ region may confer a structurally weak hyper flexible ‘hinge’
lacking in any distinct conformity through mis-folding [48]. Recently the hinge region
(NMK) was genetically engineered to vary from one to six amino acids in length, and
then tested against various pathogenic strains such as Listeria monocytogenes,
Enterococcus faecalis VE14089, Lactococcus lactis MG1363 etc. The results of an agar
diffusion assay showed that some variants with one or two amino acids extra or less
(+2,+1,−1,−2) exhibited higher activity than the wild type nisin [49]. These studies
supported positive impact of the hinge region variability of nisin toward its bioactivity
and specificity.
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Taking advantage of bioengineering technology and the site-directed mutagenesis,
Evelyn et al. have utilized the techniques and generated a bank of nisin A derivatives in
which K12 was substituted with all other standard amino acid residues Fig (2) [50]. The
study demonstrated that altering the K12 residue of nisin A can generate peptide
analogues with better antibacterial activity. The finding showed enhanced activity
towards food associated strains of bacteria and suggested that standard industrial nisin
purification/fermentation methods could be utilized [50].

Fig. (2). Bioengineering technology showed enhanced bioactivity of the wild type
lantibiotic nisin A. Mutation at lysine 12 showed enhanced, decreased or abolished
activity of Nisin A as indicated above.
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Nisin is also used as a template for designing novel peptide-based antibiotics to improve
its drug-like properties. In this regard, several research groups have focused on
development of a nisin hybrid and a synthetic active bioconjugate for nisin. A study by
Slootweg Jack et al. reported the development of a nisin hybrid with comparable activity
to the native nisin [51]. The study involved digestion of the full-length nisin between
ABC ring and DE ring regions using chymotrypsin treatment. The ABC ring was
subsequently functionalized at the C-terminal with two different amino alkyne moieties.
The nisin hybrids were prepared using the Cu(I)-catalyzed azide alkyne cycloaddition
‘click’ chemistry by chemo-selective ligation of the ABC-alkyne with the N-terminal
azido functionalized dicarba-DE ring mimic Fig (3a). The new products had similar
activity to the wild-type nisin and showed strong binding to lipid II. Similarly, synthetic
nisin derivatives made by C-terminal modifications were able to retain both the
antimicrobial activity and the membrane permeabilizing properties of the wild-type nisin,
suggesting the importance of the ABC rings and the C-terminal modification of nisin
does not deteriorate the biological activity in sharp contrast to the N-terminal
modification Fig (3). The reported studies compare well with previous studies with
regard to the important role of the AB ring. Arnusch et al conjugated nisin to vancomycin
and the conjugate exhibited 40-fold enhancement in biological activity [52]. Here the
nisin fragment (1-12) that binds to the polyphosphate moiety of lipid II was prepared by
enzymatic cleavage and was C-terminally conjugated to vancomycin using the click
chemistry [52].
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Fig. (3). Structures of Nisin-conjugates. (A) Nisin hybrids A and B that show
comparable activity to the wild type nisin A. (B) Nisin fragment (1–12) conjugated to
vancomycin that shows 40-fold increase in activity.
In contrast to the C-terminal modification, N-terminal modification of nisin is generally
problematic, as it may hinder the peptide binding to the target lipid II. Although the exact
details are not clearly understood, it is been suggested that rings A and B, which are
towards the N-terminal, bind to the cell wall and form a cage-like structure with the
pyrophosphate moiety of lipid II. As a result of this complex, the D and E rings, which
are at the C-terminal, are positioned in such a way that they can form pores in the cell
membrane of the target. Thus, losing the initial binding part or the “N-terminus region” in
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the case of nisin will stop the activity at the first place.

In agreement with the

phenomena, PEGylation of nisin at the N-terminus completely diminished its activity
[53]. While truncated mutants lacking the C-terminal rings display some antibacterial
action as it has been discussed previously.

As yet, nisin is the only lantibiotic bacteriocin that has reached the market with a
widespread use as food preservative [54]. Nisin’s wide application as a safe alternative to
chemical agents in food products with no bacterial resistance has stimulated expansions
of the research in lantibiotics towards the development of new lantibiotics with better
bioactivity and no resistance. Despite its use in food industry, nisin is still far away from
the clinical applications and that is due to a number of obstacles that still remain to be
resolved [55, 56]. The pharmacokinetic and in vivo properties of nisin need to be
optimized for clinical use. However, by better knowledge of lantibiotics’ SARs, it would
be possible to modify these antimicrobial peptides to circumvent barriers that hinder their
medical applications. In addition, SAR will allow the development of novel antibiotics
with superior activities and no resistance.

2.2

Microcin J25 (MccJ25)

Among all discovered microcins, MccJ25 is the most well studied microcin up to date. In
1992 Salmon et al. for the first time isolated and characterized MccJ25 as 20 amino acid
peptide with blocked N-terminal amino acid [57]. Later on, Blond et al. in 1999 reported
a head-to-tail ring 21 amino acid macrocylic peptide [58]. In 2003, three research groups
independently testified that J25 is noose-like ring peptide rather than head to tail [59-61].
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The sequence of J25 is rich in hydrophobic amino acids and back bone folded in very
unusual lasso structure, the carboxyl functional group of side chain of Glu8 and Nterminal Gly covalently linked and formed small lactam ring like structure and c-terminal
squeeze through this ring to form lasso (Fig 4a). This lasso structure stabilized by
aromatic side chain of Phe19 and Tyr20 located on either side of the ring prevents
slipping out c-terminal tail. This unusual noose structure of J25 provides great stability
against adverse condition like high temperature, proteases and chaotropic agents.
However, in very harsh acidic environment or in the presence of endopeptidases like
thermolysin the loop produces two-chain peptide without removing the c-terminal tail
threaded through macrolactam ring [62, 63]. This plasmid encoded posttranslationally
modified antimicrobial peptide exhibit potent activity (MIC ~ 2–50 nM) against
Salmonella species and non-producing E. coli strains. The potent narrow spectrum
antibacterial activity of MccJ25 is gained through stalling the secondary channel of RNA
polymerase, inhibiting membrane respiratory chain and dissipating diffusion potential
across the cytoplasmic membrane after getting access through siderophore receptor fhuA
of outer membrane and inner membrane complex [64].

In order to understand the importance of sequence over conformation, several groups
designed different analogues considering different parameters. In 2004, Bollomio et al.
noticed that thermolysin cleaved J25 does not inhibit E coli growth but shows in vitro
inhibition of the RNA polymerase activity [65]. Similarly, Somenova et al. reported that
chemically degraded b-hairpin region (13 - 17 and 15 - 17) analogue of J25 still exhibits
comparative RNA polymerase inhibition [66]. Furthermore, in 2008 Pavlova et al.
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Fig. (4). Diverse analogues of MccJ25. (A) MccJ25 cartoon structure with different
colour represents the effect of substitution over antibacterial activity. blue; almost
complete loss of antibacterial activity for any studied substitution, white; approximately
70% reduction observed for all studied analogues; green represents the positions where
substitution showed approximately comparable or maintenance of more than 70% of the
peptide activity and yellow; where substitution of approximately all different amino acids
show activity similar to or higher than the native McJ25. (B) Analogues of MccJ25 where
elongation, deletion, and cyclic replacements in the peptide sequence effects biological
activity. Analogues 1-6 are synthetic peptides, whereas analogues 7-10 are generated by
site-directed mutagenesis.
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genetically designed 381 analogues of J25 by substituting each amino acid (from 1-7 and
9-21) with different amino acids [67]. They observed that certain amino acid residues are
essential and play key role in the peptide biosynthesis, stability of the analogues,
inhibition of the RNA polymerase and also in permeation of the target cell membrane.
For instance, positions 1, 2 and 8 (Gly1, Gly2 and Glu8) are indispensable for production
of stable analogues, position 9 (Tyr9) is important for RNA polymerase inhibition, and
positions 4, 7, 10, 19 and 20 (Gly4, Pro7, Phe10, Phe19 and Tyr20) are essential for
growth inhibition [67]. Altogether, these reports suggest that loop is essential for cell
permeation, while the macrolactam ring and certain positions within the ring and adjacent
to the ring along with the tail stabilizing position are essential for growth inhibition
and/or RNA polymerase inhibition.

To further conclude the extent of tolerance of modification of different segments of
MccJ25, Link’s group from Princeton University derived more than 100 active analogues
through site directed mutagenesis with concurrent multiple substitutions in loop/tail as
well as the macrolactam ring [68]. As we have seen from the earlier reports of Pavlova et
al. the loop plays crucial role in permeation across cell membrane (interaction with outer
membrane receptor FhuA for their import) [67]; however Link’s group found that along
with the loop, some positions of the ring are also crucial for this interaction. It has also
been validated that the loop or the tail is more tolerable for modifications than the ring
with respect to the antibacterial properties [68].
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In order to understand the importance of lasso topology in antibacterial activity, our
group designed synthetic analogues of MccJ25 by introducing disulphide bridge to
replace the amide bond ring, increasing the size of ring, end to end cyclization, or
substitution of certain residues [69]. Two synthetic peptides (1 and 6, Fig 4b) active
against Salmonella newport were derived from the sequence of MccJ25 in this study.
One analogue contained an additional disulphide bridge between C-terminus and middle
of lactam ring and the other was with amide bond replaced with disulphide ring. Both
displayed about 25-50 fold reduced activity compared to MccJ25. Additionally, these
synthetic analogues did not fold into a lasso conformation suggesting that the topology
could be the reason behind the significant reduction in the activity [69]. Similar to
MccJ25, the synthetic analogues displayed minimal toxicity toward mammalian cells and
were found to act specifically on Gram-negative bacterial strains. Among other reports,
Ducasse et al. provided insight on different positions of ring and hairpin loop of McJ25
for maintaining the topology of lasso structure and their importance in antibacterial
activity. The authors found that Tyr20 plays crucial role in maintaining lasso topology.
In addition, Gly21 is also important for stabilizing threaded tail across the ring for the
lasso topology [70]. Increasing lariat or ring size to 9 residues by incorporating extra
amino acids or deletion of C-terminal Gly21, turn the lasso topology into branched
cyclic, which led to a complete loss of activity [70]. Substitution of the C-terminal Gly21
with Asn, Asp or Glu, or increasing the length of the tail by Gly22 does not terminate
peptide activity, however, the antibacterial activity was reduced (Fig 4b).
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Piscota et al developed substituted analogues of MccJ25 using unnatural amino acids at
positions Val6, Ile13, Phe10 and Phe19 through site directed mutagenesis [71]. Previous
studies showed that substitution of Phe10 and Phe19 even by natural amino acids
abolished antibacterial activity either completely or multiple folds; however, this study
reported that substitution with non-canonical amino acids at stated position do not show
any detrimental effect over activity. These data suggest that most likely the topology
plays a crucial role in maintaining the activity [71], and opens the door toward production
of new variants of MccJ25 with a potential for broad spectrum and potent anti-bacterial.

It is clear from the SAR studies that MccJ25 and analogues execute their function
through inhibition of RNA polymerase and/or respiratory chain of targeted bacterial cells.
In order to exhibit these intracellular activities the peptide gets access through exploiting
one of ferric siderophore complex receptor FhuA of closely related Entrobacteriaceae.
Lately, Mathavan et al successfully developed and solved crystal structure of the
complex of FhuA with MccJ25 [72]. In the study they have elucidated the role of ring by
substitution with charged or uncharged amino acids and role of loop in establishing the
proper interaction for import of J25, and functionally validated these through competition
experiment with T5 phage which utilize same receptor for injecting DNA material into
bacterial cells. The structure activity relationships for MccJ25 from a large number of
reports suggest lasso topology has a great potential for developing novel antimicrobial
agents.
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2.3

Microcin B17 (MccB17)

MccB17, a narrow spectrum antimicrobial peptide, exhibits antibacterial activity through
utilizing receptor mediated intracellular targeting process [73]. In general, most of the
narrow spectrum and potent antimicrobial peptides of bacterial origin use some specific
membrane receptor protein or essential nutrient channel for permeation across the
membrane. MccB17 uses the outer membrane protein poring OmpF and inner membrane
SmbA for permeation across the cell membrane. MccB17 exhibits potent activity against
a wide range of Gram-negative bacteria like E. coli, Salmonella, Pseudomonas and
Klebsiella by inhibiting the replication through down regulation of enzymatic activity of
type II topoisomerase (mainly known as DNA gyrase) [73-77].

Initially it was

discovered as ribosomally synthesised peptide antibiotic requiring at least four genes but
molecular mass observed for the peptide was lower than expected from DNA sequence.
The peptide undergoes extensive posttranslational modification by seven cluster gene
mcb A to G from the E. coli harboring conjugative plasmid pRYC17 (also known as
pMccB17) [78]. The early chemical analysis report indicated that many residues of the
peptide are posttranslationally modified, however, Jung’s group in 1993 and Kolter’s
group in 1994 highlighted that the peptide undergo exceptional posttranslational
modification involving backbone and generation of four thiazole and four oxazole rings
by condensation and dehydrogenation of four Ser, four Cys and six Gly residues [78, 79].
Later on, clearer image of previous findings about posttranslational modification and
unusual oxazole, thiazole and bis-heterocyclic (oxathiazole and thiaoxazole) structure
formation in the backbone of the peptide were given. The authors also alleged that this
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bis-hetrocyclic structure plays a crucial role in gyrase inhibition mediated antibacterial
activity [80, 81].

After the discovery of MccB17 in 1976 by Asensio et al. [82], Moreno group in 1985
identified that this peptide exhibit antibacterial activity through inhibition of DNA
replication by down regulating DNA gyrase activity specifically targeting -subunit of
DNA gyrase [83]. A non-ribosomally derived peptide anticancer agent bleomycin
contains bis-homocyclic thiazole ring, executes anticancer activity through directly
binding with DNA and producing double strand break. The structural component bishomocycle of thiazole ring of bleomycin provided a great derive to dig out the role of
similar structural component of B17 in gyrase mediated antibacterial activity [84].

In earlier reports of B17 for structural and posttranslational modification elucidation, it
was found that substitution of Gly24 with Gln reduced the antibacterial activity of the
peptide. It was proposed that the cause for reduced activity is due to the deletion of fourth
thiazole ring, which further hindered the cyclization at downstream residues. In other
study, the substitution of all four oxazole rings with thiazoles completely abolished the
activity. Furthermore, to determine the role of bisheterocylic structure of thiazole and
oxazole ring of B17 in inhibition of DNA gyrase activity in vitro and antibacterial
activity, several analogues derived through site directed mutagenesis by Walsh group and
collaborators were developed [85]. The sequence of B17 contains two bisheterocycle of
thiazole and oxazole, one toward the N-terminus designated as site A (Oxazole-Thiazole)
and another towards the C-terminus called site B (Thiazole-Oxazole) as shown in Fig.
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(5). Several modification of these heterocyclic structures were attempted, namely, site A
G13-S14-C15 (A GSC) modified to A G13-C14-C15 (A GCC), G13-S14-S15 (A GSS) and G13G14-C15 (A GGC), and site B G28-C29-S30 (B GCS) modified to B G28-C29-C30 (B GCC),
G28-S29-C30, (B GSC), G28-G29-S30 (B GGS), G28-G29-C30 (B GGC) and G28-G29-G30 (B
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Fig. (5). Structure of MccB17 and analogues. The bis-heterocyclic sites that were altered
in the MccB17 analogues are labeled A and B, and the modifications made are shown
(drawn) below each site.
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GGG). Through in vitro gyrase inhibition or determination of the extent of cleaved
double stranded DNA assay and antibacterial efficacy, it was observed that modification
of site B led to drastic decrease in activity. Modifications like site B “Thiazole-Oxazole”
modified to “Oxazole-Thiazole”, “Oxazole-oxazole” or “Thiazole-Thiazole” observed
more than 70% decrease in antibacterial activity. However, when site B modified into
single ring (Thiazole or Oxazole) or no ring reduced the activity was more than 90%.
While site A “Oxazole-Thiazole” modification to “Thiazole-Thiazole” did not show any
effect on the antibacterial activity, the modification to “Oxazole-Oxazole” reduced
activity by almost 30% [85]. Furthermore, a natural minor variant “+MccB17-43” (9 ring
peptide) shows more potency in vitro as well as in vivo than the major natural forms of
B17 “MccB17-43 (8 ring peptide).

Asensio et al. found that peptide B17 loses activity at extreme pH (1 and 12), by
treatment with pronase and subtilisin but remains active even after boiling at 100 °C for
30 mins [82]. Later Parks et al. found that at high pH Asn53 and Asn59 deamidate into
aspartate and resultantly lose activity in vitro as well as in vivo [86]. In a molecular
modeling study, the authors found that these residues reside on surface and deamidation
to aspartate generates negative charge which may be a probable trigger for unfavorable
interaction with DNA gyrase complex [86]. Thompson et al. degraded B17 chemically
and enzymatically, and found that the chemically degraded mixture shows inhibition
towards supercoiling and relaxation activity of gyrase, however, the ability to stabilize
DNA-gyrase complex was lost [87]. The enzymatically cleaved mixture on the other
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hand, showed all three in vitro activities. Another group tried mutations in B17 with
lysine at different positions (to cleave at specific position with trypsin) as well as
introduced stop codon to produce multiple analogues with truncated N-terminus and Cterminus peptides (Fig 6). Deletion of one, two or three amino acids from the C-terminus
dropped stabilization of cleaved DNA gyrase complex abruptly or completely, whereas
truncation of N-terminus 8-11 amino acid or synthetic analogue Mcc [Gly46-Ile69]
showed activity similar to full length B17. The same group also synthesized combination
of several N-terminal tail (11 amino acid tail of N-terminus) truncated, A and C site
mutated analogues to find the role and importance of sites A, C and the N-terminus. The
truncation of N-terminus tail up to 20-amino acids did not exhibit significant effect on
DNA cleavage activity except one analogue. This analogue showed 2-3 fold higher
activity than the full length sequence. Modification of the A and C sites in full-length
peptide revealed approximately 50% decrease in activity. In contrast in vivo study
(antibacterial efficacy) for all the analogues, except the above mentioned tail truncated
analogue, showed partial or no activity at all. Only A and/or C site modified analogues
showed 50-70% activity of the wild-type peptide. In 2014 Severinov group stepped up to
find the role of C-terminus, specially, the last three amino acids on in vitro DNA
cleavage (cleaved DNA Gyrase complex stabilization) and in vivo antibacterial efficacy
[88]. Through site-directed mutagenesis, various C-terminus truncated or substituted
(especially after two oxazole rings of B site) analogues were derived. Similar to previous
results, deletion of even one amino acid of C-terminus showed in vitro and in vivo
detrimental effect toward peptide activity [88].
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Fig. (6). DNA cleavage (Cleaved DNA-Gyrase complex stabilization) and antibacterial
activity of MccB17 and its analogues from different study [88]. A, B and C are sites of
bisheterocyclic structure and modification.

2.4 Microcin C (MccC)
MccC is a naturally occurring potent antimicrobial peptide produced by several strains of
E. coli. It consists of a 7-mer peptide with a formylated N-terminal methionine and a Cterminal aspartate whose α-carboxyl group is covalently attached to adenosine through an
N-acyl phosphoramide bond [89, 90]. Peptide MccC acts as a prodrug; it is digested first
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inside the target cells by peptide deformylase which removes the N-terminal formyl
group, followed by several aminopeptidases that remove the small peptide portion
releasing the active processed moiety, aspartyl-phosphoramidate adenosine or processed
MccC (Fig. 7A) [89]. This active compound is a mimic of aspartyl adenylate, and a very
potent inhibitor of aspartyl-tRNA synthetase (AspRS), which locks protein synthesis at
the translation step. It is believed that MccC penetrates the outer membrane of E. coli
mostly through the OmpF porin, but also through other, yet-unidentified transport
systems. The peptide then penetrates the inner-membrane via the ABC transporter
YejABEF, which is the only transporter used for transporting microcin into the cytoplasm
[91, 92].

The unique mode of action of MccC, for which the final processing steps occur inside the
target bacteria, has made it an attractive model for elaborating analogues, targeting other
aminoacyl-tRNA synthetases. A series of MccC analogues, which retained the initial
Trojan horse mechanism of antibacterial activity displayed by the natural MccC, have
been reported. In order to prove the major impact of the N-terminal formyl moiety in the
peptide biological activity, a study by Kazakov et al. showed that derivatization of the
formyl group at the N-terminal methionine effects the biological activity and decreases
the growth of inhibition far below than that was displayed by the native MccC peptide
(Fig 7B) [93].
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Fig. (7). (A) Structures of Microcin C or MccC (R1=CHO), the deformylated variant
(R1=H) and the processed MccC. (B) Structures of different MccC derivatives.
Deformylation of the N-terminal decreases biological activity of the peptide. Analogues 3
and 4 displayed much lower activity than the native peptide (MccC, R1 = CHO) and
analogue 2. (C) SARs of more than 100 mutants of MccC. The native MccC is shown as
mix of encoded circles and chemical structure. Mutations are revealed in colored letters.
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The mature MccC produced is shown above the native, while the immature MccC is
displayed below the native sequence. Substitutions indicated by a red color resulted in
growth inhibition zones that were comparable to that produced by cells producing nativetype MccC. Cells producing MccC with substitutions indicated by a blue color did not
produce biological activity by lawn assays. (D) Three synthetic analogues of MccC,
where the mutation has taken place at residue seven; sulfamoyl linker is used instead of a
phosphoramidate linker, and N-terminal formyl moiety has been cleaved. (E) Various
analogues of MccC as shown.

The site-directed mutagenesis were applied to MccC gene and a large set of MccC
analogues were produced [94]. As seen in Fig 7C, among a 114 substitutions in the lead
peptide, only 28 substitutions did not significantly alter the bioactivity of the peptide.
Four additional substitutions did not affect MccC maturation but seemed to interfere with
uptake or processing. Thus, approximately 30% of the substitutions in the peptide
resulted in functional or partially functional mature microcin. The study showed a list of
acceptable substitutions in the MccC precursor peptide that could facilitate the chemical
synthesis of microcins with altered specificity allowing to select functional peptide
sequences that can be efficiently conjugated with the nucleotide moiety of MccC.

A study by Vijver et al. reported three analogues for MccC that were synthesized to have
different amino acids at the seventh position of the peptide [95]. These analogues have
Asp, Glu, or Leu at the position seven. The analogues lack the N-terminal formyl moiety
and have a sulfamoyl linker instead of a phosphoramidate linker and unlike the native
MccC the O-aminopropyl group was left out in these analogues (Fig 7D). In contrast to
other studies, these analogues proved to be active and worked by the same mechanism as
the wild type MccC despite lacking the N-terminal formyl group [95]. The finding
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suggested that the analogues were internalized by the YejABEF peptide transporter and
metabolized by three broad-specificity peptidases PepA, B and N.

Following new synthetic strategies, the same group reported development of new
synthetic analogues of MccC to improve the yield of synthetic peptides and extend the
range of MccC-like compounds.

Although new series of MccC analogues were

developed and synthesized with better yields in comparison to previous protocols, the
biological activities of the peptides were in the same range as observed for the native
MccC (Fig 7E) [96].

Despite potent antibacterial activity of microcins in vitro and in vivo, these AMPs are not
yet approved for clinical applications. Apart of other studies, the pharmacokinetic and in
vivo properties of microcins need to be optimized for clinical use. SARs studies certainly
highlight the potential of these AMPs and should encourage the development of these
AMPs into novel antibiotics with greater activities toward pathogenic and resistant
bacteria.

3. CLASS II BACTERIOCINS
Class II bacteriocins are non-lanthionine containing bacteriocins that are not exposed to
extensive post translational modifications (Table 1). In general, they are divided into
several subclasses, class IIa, class IIb (the two-peptide bacteriocins), class IIc (cyclic
bacteriocins), class IId and IIe [1, 24, 97]. Class IIa, which is also known as pediocin-like
bacteriocins, consists of the anti-listerial one-peptide with one or two disulfide bonds and
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a conservative N-terminal motif [98, 99]. The class IIb bacteriocins, also known as the
two-peptide bacteriocins, contain two different peptides that achieve optimal antibacterial
activity by the presence of two peptides together at equivalent concentrations [100, 101].
Class IIc are the cyclic peptides, where the N and C-termini are covalently linked
resulting in a cyclic structure. Class IId bacteriocins, also referred to as the linear nonpediocin-like peptide bacteriocins, show no sequence similarity to the pediocin like
bacteriocins [24, 97].

Finally class IIe are similar to class IId but with more

modifications like siderophore conjugation.

In this review we focus mainly on the recent structural-activity relationship of class II
bacteriocins produced by lactic acid bacteria and their latest developed analogues. In
particular we will pay attention to the most well characterized bacteriocins that were
highlighted in Table 1, namely, Pediocin PA-1, Leucocin A, and Sakacin P.

3.1 Class IIa Bacteriocins
Pediocin PA-1
Pediocin PA-1 is one of the well-understood bacteriocin that exhibits inhibitory activity
against foodborne Listeria monocytogenes at nM range of concentrations [102]. The
structural functional relationship of pediocin PA-1 was evaluated by generation of several
mutants either by chemical synthesis or by the use of site-directed mutagenesis [97]. To
mention some, a study by Tominaga et al. showed the essential residues for maintaining
the bioactivity of pediocin and the structure function relationship using a technique
termed NNK scanning [103]. In their study, each residue of the native codon was
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replaced with the NNK triplet oligonucleotide using the NNK scan and the 35 generated
peptide mutations were examined for antimicrobial activities. The activity was retained
by almost all analogues harboring mutations at K1, T8, G10, S13, G19, N28, and N41,
while the activity was completely abolished by many of the mutations at residues Y2, G6,
C9, C14, C24, W33, G37, and C44, signifying that these residues are critical in the
peptide. While 14 substitutions were inactive at G6, 11 replacements were inactive at
position C14 [103].

In a recent study, nine mutants of pediocin PA-1 were generated with a variety of
substitutions and increasing number of positively charged residues. There was two-fold
increase in the activity of some generated analogues [104]. The bactericidal activity of
mutant 0K was equal to that observed for the wild-type Pediocin PA-1 (Fig 8). The
analogue S13K was somewhat more potent than the native Pediocin PA-1, indicating that
additional charged residues at position 13 has a positive impact on activity. Moreover, the
mutant 0K + S13K showed more potency than the mutant S13K, indicating the
significant role of lysine at the N-terminus in receptor recognition and binding. Contrary,
other mutants such as, 2K, G10K, 2K + S13K, 0K + 2K + S13K and 0K + 2K + G10K
had abridged pediocin potency. The finding suggested that the electrostatic interactions
between the peptide and the target bacterial cells are drastically affected by insertion of
additional cationic amino acid residues [104].
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Fig. (8). Variants of pediocin PA-1 with substitution with charges lysine residue(s).
Residues in green color denote almost similar activity, blue colored residues represent
moderate activity, and residues in red color represent loss of activity.
The structure activity relationship of pediocin-like bacteriocins, suggested that the N- and
C-terminus of bacteriocins may function independently to some extent. Specific hybrid
bacteriocins from N- and C-terminal regions of different Pediocin-like bacteriocins
revealed that the C-terminus half of these bacteriocins are important for the target cell
specificity, indicating that the C-terminal of pediocin must interact with an entity in the
surface membrane of the target cells [105]. In agreement with this finding, a similar
study, where the C-terminus of pediocin exposed to substitutions by mutagenesis, showed
that mutated peptide differ from the parental pediocin in their target specificity [106].
Likewise, a previous study by Fimland G et al. showed that a 15-mer peptide fragment
derived from pediocin PA-1 (from residue 20 to residue 34) was able to inhibit the
biological activity of pediocin [107]. Although the derived-fragment showed abolishment
of pediocin bactericidal activity and with less extent to enterocin, it did not display any
inhibition to other pediocin-like bacteriocins. It’s been suggested that a competitive
interference with the pediocin target entity on the bacterial cell membrane is behind this
effect of inhibition. One protein that appears to be involved in such an interaction is the
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membrane-associated mannose phosphotransferase system permease, which is found in
the surface membrane of the targeted bacterial cells. Recently, two hybrid bacteriocins,
enterocin E50-52/pediocin PA-1 and pediocin PA-1/enterocin E50-52 designed by
switching the C and N terminus domains, showed reduced MICs in comparison to those
of their natural counterparts. [108] .

Several investigations were performed in the last decade with pediocin PA-1 and a
majority have been reviewed elsewhere [98, 109-111]. Despite the fact that pediocin PA1 has been empirically used for many years, most of the current knowledge on pediocin
PA-1 that were generated is not enough to translate it to a therapeutic product. Pediocin
PA-1 has been the subject of considerable interest for many years. However, there are
still many aspects that need further research and investigation. The structure and mode of
action are still far from completely elucidated. Establishing the relationships between
pediocin structure and its biological activity is of particular interest because this
knowledge may enable to boost its activity and generate understanding of the
mechanisms of bacterial resistance to the peptide. We believe peptide engineering,
genetically and/or by chemical synthesis would lead to the development of new AMPs
with improved properties based on some features of the pediocin PA-1 antimicrobial
peptide.

Leucocin A (LeuA)
LeuA is another potent AMP from class IIa bacteriocins active against Listeria
monocytogenes in the nM range (MIC 37 nM) [112]. Like pediocin PA-1, LeuA consists

36

of C-terminal amphipathic alpha helix and N-terminal with β-sheet-like structure beside
the conservative YGNGV motif. LeuA is 37 residues long and features one disulfide
bond between C9 and C14 (Fig 9a).

Historically, LeuA was first isolated from

Leuconostoc gelidum UAL 187 by Hastings et al. in 1991 [113] and the first structure
elucidation and confirmation was performed by Vederas et al. in 1997 [114]. Due to its
potent activity, LeuA has received considerable attention and the SARs are still a popular
topic for the ongoing research.

One of the first analogues of LeuA was an all D-amino acid enantiomeric peptide, where
the entire peptide was made from D-amino acids instead of L-amino acids [115]. The DLeuA was not active demonstrating involvement of a chiral docking molecule for the
peptide mechanism of action. Year later, a mutagenesis of mpt operon in Listeria
monocytogenes [116], generated a peptide-resistant bacteria enabling scientists to find a
particular enzyme-domain as a potential receptor for class IIa bacteriocins. The findings
were confirmed further by other studies, where all suggested that a particular domain/or
subunit of mannose phosphotransferase system – a receptor that transports sugar through
the cytoplasmic membrane and phosphorylates it as it pass into the intracellular system –
is responsible for the biological activity of peptide, as it serves as a target receptor for
class IIa bacteriocins [117, 118].

Several hypothesis came in to explain how class IIa bacteriocins exert their biological
actions. It is believed that the C terminal domain of the peptide recognizes a particular
target on the surface membrane of the bacteria and then the N-terminus binds the cell
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surface by electrostatic interactions, and together exert the killing action through the pore
formation [98]. To understand the significant role of the disulfide bridge of LeuA towards

Fig. (9). (A) Structure activity relationship (SAR) of LeuA was studied by addition,
deletion and/or amino acid substitutions. Analogues led to loss in the biological activity,
indicating importance of the topological structure of LeuA. (B) Leu A analogues made
by replacement of the cysteine residues at positions 9 and 14 by other amino acids. While
allylglycine, phenylalanine, leucine and norleucine showed comparable activity to the
wild-type LeuA, bis-serine abolished activity.
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the bactericidal activity, Vederas et al. synthesized analogues of LeuA, where the
disulfide bridge was replaced by carbocyclic moiety (Fig 9b) [119].

Analogue where serine takes place of cysteine 9 and 14 showed no observable activity,
whereas replacement of disulfide bridge of LeuA with allylglycine residues without ring
formation delivered a LeuA derivative (diallyl-LeuA) with comparable bactericidal
activity to the wild-type LeuA. The finding has motivated to synthesize further acyclic
analogues of LeuA, wherein disulfide bridge (positions 9 and 14) were replaced by
hydrophobic residues such as norvaline, leucine and phenlyalanine [120]. Interestingly
these analogues also showed comparable activity to the wild-type LeuA. Apparently the
hydrophobic resides hold the loop between residues 9 and 14 close together via
hydrophobic interactions and thereby maintain the peptide topological conformation
necessary for the activity. By contrast, the bis-serine analogue that shows diminished
activity could have insufficient bonding (H-bonding) to maintain the conformational
stability of the peptide.

In order to elucidate the structural–functionality of the N-terminal domain of LeuA, our
group designed a number of analogues of the LeuA by replacing the N-terminal β-sheet
with shorter β-turn motifs [112]. The study showed that such replacements eradicate the
bactericidal activity of the peptide. One analogue, however, was able to show competitive
binding inhibiting the activity of wild-type LeuA. This study suggested the role of proper
folding and complete sequence in the activity of class IIa bacteriocins. We also showed
for the first time that surface conjugated LeuA (37-residue) shows antibacterial activity
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using a live/dead cell assay, while surface conjugated 24-residue C-terminal fragment of
LeuA was not active [121]. [122, 123]. [124]. The results indicate that although the Nterminal region has a vital influence on the activity of the peptide, additional interactions
at the C terminus with the receptor must match and contribute to the overall activity.
More analogues are under investigation by our group, in particular concerning the
potential of LeuA as a recognition element in biosensing devices for detecting Listeria
monocytogenes. Likewise, SARs studies of LeuA are ongoing and analogues with higher
stability and better potency are under development.

Sakacin P
Sakacin P is a class IIa bacteriocin produced by Lactobacillus sakei. Like Ped and LeuA,
it displays strong activity against certain food-borne pathogens such as Listeria
monocytogenes. It consists of 43 amino acids and has a structural similarity to pediocin
PA-1 [125]. Few studies have been performed to explore the SAR of sakacin and here we
will discuss some of the notable examples. Fimland et al. showed that the introduction of
the C-terminal disulfide bridge into sakacin P particularly broadens the target cell
specificity and increases the potency at elevated temperatures. Contrary, removing the Cterminal disulfide bridge in pediocin PA-1 decreases it potency and biological stability
[126]. The SARs of the N-terminal domain of class IIa peptides has also been explored
through modifications of the N-terminus of sakacin P using site-directed mutagenesis
(Fig 10) [127]. To explore the significant role of the charged residues at the N-terminus
in binding to the target cells, the residues were substituted with other amino acids and
tested for biological activity [127]. Interestingly, in all mutations a decrease in the net
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positive charge causes a reduction (2-15 folds) in peptide potency. The least lethal of
these mutations was the replacement of His (H8) by Thr (T8). Interestingly, this mutation
did not show lethal effect in potency of the peptide, indicating that the positive charges at
position 8 have no major role. The most lethal effect to the peptide’s activity was
observed during substitution of the positive charges at the N- and C-terminal ends (K1T,
K43T), signifying the importance of the cationic moiety in class IIa bacteriocins [127].

To gain insight on how the N-terminus β-sheet-like domain in sakacin P positions itself
on the bacterial membrane, substitutions at the conservative motif domain (YGNGV)
were designed [128]. The biological activity of the mutant peptides was then investigated

Fig. (10). Site-directed mutagenesis of the N-terminal domain of sakacin P. Green
mutations are more active, blue are moderate and red are inactive.
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and the peptide-binding studies were explored using the peptide-liposomes interactions.
The results showed association of the N-terminus domain with only anionic liposomes
[128]. The study showed also the impact of the electrostatic interaction in penetration of
some peptide residues into the liposomes. Further, the biological activity study revealed
that the two mutants, Y2L and Y3L resulted in a 10-fold reduction in activity, whereas,
mutants Y2W, Y2F, Y3W and Y3F were tolerated fairly well. Furthermore, the V2I
mutant had no effect in the activity. The mutant, G6A was highly detrimental, consistent
with G6 being in one of the turns in the β-sheet-like N-terminal domain. The finding
suggested that both the polar amide group on the side chain of N5 and its position in
space have significant role in the peptide to be fully active. The study also explained the
mechanism and significant role played by hydrophobic residues in positioning the peptide
residues on the membranes of the target cells [128].

Throughout the investigational studies of class IIa bacteriocins there is a hope set by
these potent peptide to deliver future antibiotics against dangerous pathogens. Class IIa
are relatively small peptides (37-48 residues) produced without posttranslational
modification or processing making them relatively easy to obtain and modify either by
gene expression or using the standard peptide synthesis methods. The high specificity of
class IIa bacteriocins against foodborne pathogens, and specifically Listeria
monocytogenes makes them ideal candidate to solve issues like foodborne outbreaks with
potential in food and pharmaceutical industries.

3.2 Class IIb Bacteriocins
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Class IIb bacteriocins are two-peptide bacteriocins that consist of two different peptides
where optimal antibacterial activity is achieved only by the presence of these peptides
together in equal quantities (Table 3) [100, 129, 130]. Majority of class IIb bacteriocins
whose mode of action has been investigated render the cell membranes of the target cells
permeable to a variety of small molecules [101]. For instance, Lactococcin G (LcnG)
targets the cell membrane and allows a variety of monovalent cations to permeabilize
such as, Na+, K+, Li+ Rb+ and the choline, but not the divalent cations like the Mg++ or
the anions like phosphates or the H+. More than 15 peptides of the two-peptide
bacteriocins have been identified so far [131]; however, the three-dimensional structure
as well as the structural activity relationship of two-peptide (class IIb) bacteriocins are
not as well characterized as that of pediocin-like (class-IIa) bacteriocins [100, 131, 132].
As a result, we will limit our SAR discussion in this review to certain peptides of the twopeptide bacteriocins where analogues or mutants were introduced.

Table 3. Structure of some unmodified (class-IIb) two-peptide bacteriocins. The GxxxG
and AxxxA motifs are shown in bold.
Peptide

Sequence

Lactococcin G

LcnG-α
LcnG-β

GTWDDIGQGIGRVAYWVGKAMGNMSDVNQASRINRKKKH
KKWGWLAWVDPAYEFIKGFGKGAIKEGNKDKWKNI

Plantaricin E/F

PlnE
PlnF

FNRGGYNFGKSVRHVVDAIGSVAGIRGILKSIR
VFHAYSARGVRNNYKSAVGPADWVISAVRGFIHG

Plantaricin J/K

PlnJ
PlnK

GAWKNFWSSLRKGFYDGEAGRAIRR
RRSRKNGIGYAIGYAFGAVERAVLGGSRDYNK

Plantaricin S

Pls-α
Pls-β

RNKLAYNMGHYAGKATIFGLAAWALLA
KKKKQSWYAAAGDAIVSFGEGFLNAW
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As indicated above, the antimicrobial activity of two-peptide bacteriocins is achieved
only when two complementary peptides are combined together either from the same
peptide bacteriocin or in some cases with two homologues of another peptide bacteriocin.
As an example, LcnG showed bactericidal activity at nanomolar level of concentration
when combined, but that activity is totally lost when the peptides were tested individually
[131, 133]. No activity were observed even when combined with either the E- or Fpeptide of plantaricin E/F or the J- or K-peptide of plantaricin J/K. [134]. In contrast,
higher activity was observed when LcnG was combined with the complementary peptide
from (LcnQ) or enterocin 1071, which perhaps is a result of sequence similarities
between these peptides [100, 101, 135, 136]. The fact that two-peptide bacteriocins
function together to display antibacterial activity only when combined clearly indicates
that these peptides interact in a particular fashion to form one functional unit and single
peptide molecule. This is not surprisingly when we see that the genes encoding the two
peptides of two-peptide bacteriocins are located next to each other on the same operon,
and that the two peptides are thus produced in nearly equal quantities.

LcnG, plantaricin E/F and plantaricin J/K are the most well characterized in class IIb
bacteriocins (Table 3). The CD studies showed that these peptides are unstructured in
water, and helical formation occurs only when the peptides are exposed to more
hydrophobic or membrane-like environment such as trifluoroethanol containing media,
micelles or liposomes [137-140]. The results suggested that the peptides of the twopeptide bacteriocins interact in a structural inducing manner upon exposure to the
membrane of the target cells.
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Majority of the two-peptide bacteriocins that are explored so far compose of one or two
conserved GxxxG motifs in their sequences. These motifs are anticipated to be essential
for conjugating the two peptides together. In other words, along with the “GxxxG”-like
motifs (AxxxA, SxxxS), the motifs mediate helix-helix interactions between the two
complementary peptides of two-peptide bacteriocins and suggested a main role in
penetration of the target cell membranes [141-143]. Several mutations have been sited on
the GxxxG motif in LcnG, pln J/K and E/F in order to explore its role in peptide
interactions and thereby the effect on the peptide biological activity. Substitution of
glycine residues in the GxxxG-motifs of LcnG with larger residues that interfere with
close helix–helix contact was extremely unfavourable [144], while replacement of other
glycine residues in the peptides was fairly well tolerated. Similarly, mutations of the
glycine residues at GxxxG motifs of Pln J/K cause loss of the peptide activity, while
glycine substitutions at other positions shown no effect on the activity.

Our group explored the structure activity relationships for plantaricin S (Pls) using CD,
biological assays and molecular dynamic simulations. The study revealed that the helixhelix alignment of the two Pls peptides and interaction between the conserved motifs are
fundamental for interaction with the target cell membrane [145]. The two Pls peptides
and five Pls derived fragments were designed and synthesized. CD findings of Pls and the
designed fragments showed helical topological structure of the peptides in aqueous 2,2,2trifluoroethanol solutions. The molecular dynamics simulation demonstrated that when
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the two Pls peptides are in antiparallel orientation, the helical motifs interact and align,
mediated by strong attraction between the conserved GxxxG/AxxxA motifs [145].

In order to understand structural features that are important for activity and potency of
two-peptide bacteriocins, an extensive structure function relationship is required. It is
essential that more extensive analyses of how the peptide works, communicate and
generate their effect are performed as it is necessary for explaining further details of the
mechanism of action of peptides and give more insight on the future of engineering novel
antimicrobial peptides. Being small sized linear peptides with no post translational
modification, the two-peptide bacteriocins are valuable antimicrobial peptides that can be
exploited for rational design of new antibiotics with wide medical and biotechnological
applications.

3.3

Class II Microcins

Class II microcins are high molecular-mass antimicrobial peptides, ranging from 5 – 10
KDa. They have been subdivided into two subclasses, Class IId and IIe [146]. Class II
microcins have been less well-studied than class I microcins in regard to their structures,
mode of actions and structure–function relationships. In contrast to class IIe, class IId
peptides are characterized by disulfide bond with no further post-transitional
modifications. While class IId comprises three plasmid-encoded peptides with posttranslationally modification, class IIe consists of chromosome encoded linear microcins
that carry a C-terminal siderophore [147, 148]. Fig. (11) shows sequence alignments of
the well-studied microcins of class II microcins so far.
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Microcin L (MccL), a 90-residue peptide, is a newly discovered AMP that exhibits strong
activity against related bacterial strains, such as Enterobacteriaceae, including
Salmonella enterica serovars typhimurium and enteritidis. The partial protein sequencing
showed the 40 amino acid residues at the N-terminal of MccL [149] consist of
unmodified amino acids [150] Fig. (11). Overall, MccL consists of 90 amino acid
residues with a mass of 8,884 KDa and two disulfide bridges [151]. The MccL
antibacterial activity relies on its recognition at the cell surface membrane by a specific
iron siderophore uptake receptor. The receptor facilitates the peptide passage through the
outer membrane following a TonB and energy-dependent pathway [151]. Another
microcin, MccV, was first isolated, purified and characterized in 1994 by Kolter and coworkers from E. coli MC4100 harbouring the pHK11 and/or pHK22 plasmid. MccV
displays antibacterial activity directed against related Gram-negative bacteria with an
MIC of about 0.1 nM against E. coli. MccV is an 88-residue peptide, without posttranslational modification, which possesses a single disulfide bond connecting Cys76 to
Cys87 Fig (11). A preparation of MccV, Procin (CanBiocin Inc.), has been FDA
approved as a probiotic agent that targets specific pathogens of the gastrointestinal tract
using MccV active against pathogenic E. coli [152]. Procin reduces the incidence and
severity of scours in weanling pigs.
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Fig. (11). Sequence of five class II microcins. Peptide sequences were obtained either by
Edman degradation (Mcc E492, first 40 AA of Mcc L and 47-first of Mcc V) or
presumed from the DNA sequence (Mcc V, Mcc 24 and Mcc H47). Amino acids
coloured dark blue or light blue show the impartiality.
Microcin N (MccN), which is also known as microcin24 or colicin24 (Mcc24), is a
bacteriocin produced by the uropathogenic strain E. coli.[150] The peptide has strong
antimicrobial activity against pathogenic bacteria, such as E. coli O157:H7, Salmonella
enteritidis, and Salmonella enterica serovar typhimurium; however, it does not show
antibacterial activity against strains of Campylobacter jejuni and Listeria monocytogenes
[153]. As yet, many properties of MccN have not been characterized, neither SARs have
been elucidated [154].

In contrast to class IId microcins, class IIe backbones undergo a bit more post-transitional
modifications. In addition to the disulfide bonds, the peptides may carry a siderophore
type translational modification. MccE492 is a low molecular mass bacteriocin (7.9 kDa),
which was initially produced by Klebsiella pneumoniae RYC492 in 1984 [155]. It acts by
forming pores on the membrane of the target bacteria and decreases the membrane
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potential [155, 156]. Similarly, microcin H47 is a bactericidal antibiotic produced by a
naturally occurring E. coli strain [157]. In fact, MccH47 and MccE492 present an overall
identity of 35%, but the C-terminal regions of the molecule are more homologous. It is
noteworthy that microcins E492, 24, H47, V and L share an N-terminal hydrophobic
consensus motif GAAGGA (Fig 11). Microcins E492 and H47 are incapable to inhibit
the growth of strains carrying mutations in the FepA, Cir and Fiu genes, displaying the
necessity of the iron-catecholate receptors for their bioactivity [158-161]. It has been
demonstrated that MccE492 uptake by FepA, Fiu and Cir is co-operative, with FepA
being the main receptor [162, 163]. The activity of microcin E492 is dependent on the
use of inner membrane complexes that use the proton motive force from the cytoplasmic
membrane to transduce ATPs to the outer membrane. It has been shown that the Cterminal serine-rich region, which is highly conserved in the three characterized
siderophore-microcins deduced from gene cluster analysis [157], is not required for
activity of intracellular microcin [16].

4. CHALLENGES AND FUTURE
During the past years, bacteriocins were exposed to extensive modifications on their
sequences including substitutions of single, double or multiple amino acids, deletions and
insertion of amino acid residues, all in order to get better understanding of their
mechanism of actions and develop analogues with better bioactivity.

Two main

techniques were habitually used for these explorations of SARs. First is the genetic
manipulation, or so-called mutagenesis. Second is using synthetic amino acids and solid
phase peptide synthetic methods. The mutagenesis or more-specifically, the site-directed
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mutagenesis has been utilized to produce several analogues of bacteriocins that contain a
single substitution of amino acid [48, 104]. The technique is very useful tool in mapping
the significant role of single or multiple residues within the peptide sequence. Even
though the technique is very useful and incredible in many ways, it has a number of
limitations. At the first, it only allows replacements of one or more amino acids with
natural amino acids; in other words, it’s only limited to natural amino acid-containing
peptides [164, 165]. While it is possible to force bacteria to integrate unnatural amino
acids into the sequence [166-168], a better method could be engineering the translational
tackle, which can be achieved by generating an aminoacyl-tRNA synthetase and tRNA
pair that function self-sufficiently of the synthetases and tRNAs endogenous to the
bacteria for instance. Secondly, in order to obtain an analogue of certain peptide, you
would need to use the natural producer organism for the production to allow for the
prerequisite modification enzymes. The producing mutant peptide could have much
higher activity and stronger potency than the parent peptide; this may pass the immunity
mechanism of the producing organism causing it to death and stop any further
productions of the mutant analogue. Lastly and perhaps the main issue that face
mutagenesis is the production of the mutants itself; as the productions relies on the
modification, the desired analogue may not be produced at the first place and cannot then
be tested.

In contrast to mutagenesis, chemical synthesis has provided peptide analogues with no
restriction of amino acids [165, 169]. The analogues have been produced with unnatural
amino acids in both linear and cyclic manner [170]. The chemical route of peptide
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production is often a better technological option than the biotechnological methods for
synthesis of medium size peptides that comprise most of the pharmaceutically relevant
molecules [165]. However, its limitation comes by increasing the size of the peptide,
where insufficient synthesis takes place. Further, certain unusual amino acids are
unavailable to be introduced or if they are, it is difficult and challenging to introduce to
the sequence and maintain the active form of stereochemistry [171]. Cyclization of
certain lasso peptides has also been challenging and almost impossible so far. Another
key point in chemical synthesis is that the produced peptides can be easily separated from
impurities and side products; racemization during peptide bond formations can be a
drawback, however [172].

The use of mutasynthesis, which enables introduction of unnatural amino acids and then
subsequent use of enzymes to increase the peptide complexity, seems to offer the
advantages of both synthesis and mutagenesis [173, 174]. However, the enzymes
stabilities are the main cons of the method. Enzymes are in general labile catalysts, so the
engineering process of enzymatic reactions must be intended carefully. This implies that,
higher percentage of optimizations of the most relevant operational parameters such as,
pH, temperature, used solvents’ concentrations and the assessment of both activity and
stability are extremely vital. Despite the challenge that face approaches of designing
analogues of nature antimicrobial peptides, strategies for synthesis still continue to
develop and production of variable analogues are enduring.
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Along all these years, it has been a continuous effort to produce potent analogues of
bacteriocins that could have potential use in real applications. Advanced genomics has
increased the possibility of designing potent analogues and allowed for better
understanding of the SARs of bacteriocins. Owing to reduced cost of genome sequencing,
molecular biology approaches with genetic manipulations are considered the favourite
route to obtain new bacteriocins analogues. New features of mutants and synthetic
analogues were identified and will continue to be probed, which will lead to improvement
in the activity spectrum of bacteriocins. New analogues of bacteriocins with improved
water solubility [175] and better stability is serum and super activities have been
generated [176].

Thus, the future will bring forward new and more efficient

antimicrobial bacteriocins based on our knowledge of the biologically produced peptides.

5. CONCLUSION
With continuing exploration of bacteriocins and their SARs, our understanding of the
structure-function relationships rise and grow incessantly, leading toward the
development of new antibacterial molecules with better bactericidal activity, broader
target specificity and lower side-effects.

Knowledge of the structure activity

relationships of bacteriocins provides us with more detailed molecular analysis and
vibrant insight of the machinery by which these natural molecules are operating. The
SARs among bacteriocins will allow us to develop new antimicrobial peptides tailored
for specific applications in food industry and healthcare.
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